Operationalizing Screening for Non-Small Cell Lung Cancer: An International Discussion - Episode 2
Implementing Comprehensive Genomic Testing in NSCLC Care
Experts address the critical practice of comprehensive biomarker testing for non-small cell lung cancer (NSCLC), highlighting both its necessity and the challenges in implementation. While biomarker testing is mandatory from diagnosis per guidelines, real-world barriers like insufficient tissue from biopsies often prevent complete profiling.
To overcome this, the discussion emphasizes solutions such as repetitive biopsies, improved bronchoscopic techniques, and the vital role of liquid biopsy. Using tissue and liquid biopsy together significantly increases the success rate of achieving a full genomic profile. The conversation also highlights the importance of specialized thoracic cancer centers and structured national programs, like the one in Germany, which use a networked model for NGS testing to ensure high-quality, accessible testing and underscore why expert centers are crucial for optimal patient care.
Related Content:
